🇺🇸 FDA
Patent

US 8940896

Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis

granted A61KA61K31/4166A61P

Quick answer

US patent 8940896 (Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis) held by PTC THERAPEUTICS, INC. expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/4166, A61P, A61P17/00, A61P17/06